Showing 653 results

Filters Content type: News, Editors' picks Topic: New & experimental hepatitis C treatment

News and information about clinical trials and regulatory approval of new medications to treat hepatitis C.

New & experimental hepatitis C treatment

New second generation combination therapy for HCV - first or best in the market

Editor's pick
Seeking Alpha
19 November 2012
New & experimental hepatitis C treatment

Copy of New second generation combination therapy for HCV - first or best in the market

Editor's pick
Seeking Alpha
19 November 2012
New & experimental hepatitis C treatment

Sofosbuvir demonstrates high response rate in interferon-free combination with ribavirin and GS-5885

News
15 November 2012
New & experimental hepatitis C treatment

Gilead may move ahead of rivals with hepatitis C results

Editor's pick
Bloomberg Businessweek
15 November 2012
New & experimental hepatitis C treatment

Copy of Gilead may move ahead of rivals with hepatitis C results

Editor's pick
Bloomberg Businessweek
15 November 2012
New & experimental hepatitis C treatment

Bristol-Myers Squibb’s Investigational Hepatitis C Compounds Lambda and Daclatasvir Plus Ribavirin Achieved SVR12 in 93% of Genotype 1b Treatment-Naive Patients In Phase IIb Study

Editor's pick
HCV New Drugs Research
14 November 2012
New & experimental hepatitis C treatment

Gilead May Top Rivals With Hepatitis C Therapy Results

Editor's pick
Bloomberg BusinessWeek
14 November 2012
New & experimental hepatitis C treatment

Abbott Announces Phase 3 Interferon-free Hepatitis C Regimens to be Studied in Broad Patient Populations

Editor's pick
Abbott press release
14 November 2012
New & experimental hepatitis C treatment

94% response rate to HCV treatment without ribavirin or interferon in harder-to-treat

News
13 November 2012
Hepatitis C treatment side-effects

Reducing ribavirin and adding EPO are both good anaemia management strategies for people taking boceprevir

News
13 November 2012
New & experimental hepatitis C treatment

Achillion Provides Update on Clinical HCV Development Programs

Editor's pick
Achillion press release
13 November 2012
New & experimental hepatitis C treatment

Hep C Competitors Cede Space To Gilead And Bristol-Myers And Turn To Niche Uses

Editor's pick
Seeking Alpha
13 November 2012
New & experimental hepatitis C treatment

Gilead Climbs on Study Results of Hepatitis C Combination

Editor's pick
Bloomberg
12 November 2012
New & experimental hepatitis C treatment

Novartis' Certican succeeds in liver transplant trial

Editor's pick
Reuters
12 November 2012
New & experimental hepatitis C treatment

AASLD-GI-5005 Improves Virologic Clearance of HCV in Combination with PegIFN/Ribavirin in IL28B T/T Patients

Editor's pick
HCV New Drugs Research
12 November 2012
New & experimental hepatitis C treatment

Abbott interferon-free combination 'promising' in harder-to-treat patients with hepatitis C

News
12 November 2012
New & experimental hepatitis C treatment

High rate of response to BMS HCV drugs in harder-to-treat patients – but interferon-free prospects differ by sub-genotype

News
12 November 2012
New & experimental hepatitis C treatment

Final study results show telaprevir is safe and effective for HIV/HCV co-infected people

News
12 November 2012
New & experimental hepatitis C treatment

Gilead, Abbott Unwrap Dueling Hep C Pill Data

Editor's pick
The Street
12 November 2012
New & experimental hepatitis C treatment

New hepatitis C drugs danoprevir and mericitabine are safe and effective for prior non-responders and people with cirrhosis

News
12 November 2012
New & experimental hepatitis C treatment

ALS-2200 (VX-135), Vertex's Oral Nucleotide Analogue in Development for Hepatitis C

Editor's pick
Vertex press release
11 November 2012
New & experimental hepatitis C treatment

Twice-Daily Telaprevir Achieved Viral Cure (SVR12) Rates Similar to Those Treated Three Times Daily

Editor's pick
Vertex press release
11 November 2012
New & experimental hepatitis C treatment

Boehringer Ingelheim to start late-stage hepatitis C drug trial

Editor's pick
Reuters
11 November 2012
New & experimental hepatitis C treatment

Idenix Reports On IDX719 and IDX184

Editor's pick
Idenix press release
11 November 2012